The selenium and vitamin E cancer prevention trial

Eric A. Klein, Scott M. Lippman, Ian M. Thompson, Phyllis J. Goodman, Demetrius Albanes, Philip R. Taylor, Charles Coltman

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Background: Evidence suggests that both selenium and vitamin E reduce the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized, prospective, double-blind study designed to determine whether selenium and vitamin E alone and in combination can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiological evidence supporting a role for selenium and vitamin E as chemopreventive agents in prostate cancer are reviewed, and details of the trial design are presented. Results: Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. SELECT is a 2×2 factorial study with an accrual goal of 32,400 men with nonsuspicious DRE and serum PSA of 4 ng/ml or lower. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

Original languageEnglish (US)
Pages (from-to)21-27
Number of pages7
JournalWorld Journal of Urology
Volume21
Issue number1
DOIs
StatePublished - May 2003

Fingerprint

Selenium
Vitamin E
Prostatic Neoplasms
Neoplasms
Chemoprevention
Double-Blind Method
Randomized Controlled Trials
Placebos
Serum

Keywords

  • Chemoprevention
  • Prostate cancer
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Urology

Cite this

Klein, E. A., Lippman, S. M., Thompson, I. M., Goodman, P. J., Albanes, D., Taylor, P. R., & Coltman, C. (2003). The selenium and vitamin E cancer prevention trial. World Journal of Urology, 21(1), 21-27. https://doi.org/10.1081/MA-120016671

The selenium and vitamin E cancer prevention trial. / Klein, Eric A.; Lippman, Scott M.; Thompson, Ian M.; Goodman, Phyllis J.; Albanes, Demetrius; Taylor, Philip R.; Coltman, Charles.

In: World Journal of Urology, Vol. 21, No. 1, 05.2003, p. 21-27.

Research output: Contribution to journalArticle

Klein, EA, Lippman, SM, Thompson, IM, Goodman, PJ, Albanes, D, Taylor, PR & Coltman, C 2003, 'The selenium and vitamin E cancer prevention trial', World Journal of Urology, vol. 21, no. 1, pp. 21-27. https://doi.org/10.1081/MA-120016671
Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR et al. The selenium and vitamin E cancer prevention trial. World Journal of Urology. 2003 May;21(1):21-27. https://doi.org/10.1081/MA-120016671
Klein, Eric A. ; Lippman, Scott M. ; Thompson, Ian M. ; Goodman, Phyllis J. ; Albanes, Demetrius ; Taylor, Philip R. ; Coltman, Charles. / The selenium and vitamin E cancer prevention trial. In: World Journal of Urology. 2003 ; Vol. 21, No. 1. pp. 21-27.
@article{ff9b408036b549a8a7f9d8bb6971f673,
title = "The selenium and vitamin E cancer prevention trial",
abstract = "Background: Evidence suggests that both selenium and vitamin E reduce the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized, prospective, double-blind study designed to determine whether selenium and vitamin E alone and in combination can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiological evidence supporting a role for selenium and vitamin E as chemopreventive agents in prostate cancer are reviewed, and details of the trial design are presented. Results: Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. SELECT is a 2×2 factorial study with an accrual goal of 32,400 men with nonsuspicious DRE and serum PSA of 4 ng/ml or lower. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.",
keywords = "Chemoprevention, Prostate cancer, Selenium, Vitamin E",
author = "Klein, {Eric A.} and Lippman, {Scott M.} and Thompson, {Ian M.} and Goodman, {Phyllis J.} and Demetrius Albanes and Taylor, {Philip R.} and Charles Coltman",
year = "2003",
month = "5",
doi = "10.1081/MA-120016671",
language = "English (US)",
volume = "21",
pages = "21--27",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The selenium and vitamin E cancer prevention trial

AU - Klein, Eric A.

AU - Lippman, Scott M.

AU - Thompson, Ian M.

AU - Goodman, Phyllis J.

AU - Albanes, Demetrius

AU - Taylor, Philip R.

AU - Coltman, Charles

PY - 2003/5

Y1 - 2003/5

N2 - Background: Evidence suggests that both selenium and vitamin E reduce the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized, prospective, double-blind study designed to determine whether selenium and vitamin E alone and in combination can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiological evidence supporting a role for selenium and vitamin E as chemopreventive agents in prostate cancer are reviewed, and details of the trial design are presented. Results: Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. SELECT is a 2×2 factorial study with an accrual goal of 32,400 men with nonsuspicious DRE and serum PSA of 4 ng/ml or lower. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

AB - Background: Evidence suggests that both selenium and vitamin E reduce the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized, prospective, double-blind study designed to determine whether selenium and vitamin E alone and in combination can reduce the risk of prostate cancer among healthy men. Materials and methods: The preclinical and epidemiological evidence supporting a role for selenium and vitamin E as chemopreventive agents in prostate cancer are reviewed, and details of the trial design are presented. Results: Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. SELECT is a 2×2 factorial study with an accrual goal of 32,400 men with nonsuspicious DRE and serum PSA of 4 ng/ml or lower. Conclusions: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

KW - Chemoprevention

KW - Prostate cancer

KW - Selenium

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=0141958547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141958547&partnerID=8YFLogxK

U2 - 10.1081/MA-120016671

DO - 10.1081/MA-120016671

M3 - Article

VL - 21

SP - 21

EP - 27

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 1

ER -